Regulatory Update — ICH Guideline

ICH E6(R3) Annex 2 Finalized: GCP for Decentralized, Pragmatic, and Real-World Data Trials

Published November 2026 — What the final Annex 2 covers, where regional implementation stands, and what sites and sponsors should have in place before the EU effective date of January 15, 2027.

Background

GCP Catches Up with How Trials Are Now Run

ICH E6(R3) was written as a set of documents: an overarching Principles document, Annex 1 for traditional interventional trials, and Annex 2 for trial designs and data sources that earlier versions of Good Clinical Practice did not address directly. The Principles and Annex 1 were finalized in January 2025. Annex 2 followed on June 3, 2026, completing the revision.

Annex 2 does not replace Annex 1. It is read alongside it and adds considerations specific to trials with decentralized elements, pragmatic elements, and real-world data sources. For sites, the practical effect is that activities many have been performing under sponsor-specific procedures since 2020 now have a harmonized GCP reference behind them.

What Annex 2 Covers

The annex addresses three kinds of trial element and applies the E6(R3) quality principles to each.

DCT
Decentralized Elements

Trial activities that take place away from the traditional investigator site: remote and telehealth visits, home-based care, local or mobile healthcare providers, direct-to-participant shipment of investigational product, and digital data-collection tools.

PCT
Pragmatic Elements

Designs that sit closer to routine care, with broader eligibility criteria, streamlined data collection, and trial procedures integrated into normal clinical practice so that results better reflect the patients who will ultimately use the product.

RWD
Real-World Data Sources

Data drawn from electronic health records, registries, and claims databases. Sponsors are expected to show that these sources are fit for purpose, reliable and traceable, and appropriately governed, particularly when a third party manages them.

QbD
Risk-Proportionate Oversight

Annex 2 carries forward the E6(R3) principles of quality by design and proportionality. Oversight is scaled to the complexity and risk of the trial, with the focus kept on participant safety and the reliability of results.

Regional Implementation Status

Annex 2 is on a different schedule from the rest of E6(R3), and regions are moving at different speeds. Multi-region trials need to track both.

1

Principles and Annex 1 (January 2025)

The E6(R3) Principles document and Annex 1, which covers traditional interventional trials, reached Step 4 on January 6, 2025. They became operative in the EU on July 23, 2025, and the FDA announced its final guidance in the Federal Register on September 9, 2025.

2

Annex 2 Adopted by ICH (June 2026)

ICH adopted the final Annex 2 at Step 4 on June 3, 2026. Compared with the 2024 draft, the final text makes relatively few structural changes. It adds clarity on oversight of real-world data sources, data governance and access, participant-centered design, and handling safety information that arrives through multiple data streams.

3

EU Adoption (June 2026) and Effective Date (January 2027)

The CHMP adopted Annex 2 on June 25, 2026. It takes effect in the EU on January 15, 2027. Sponsors running multi-country trials with EU sites should treat that date as the point by which protocols, monitoring plans, and vendor agreements for decentralized activities need to reflect the annex.

4

United States: Awaiting FDA Publication

The FDA issued Annex 2 as a draft guidance in December 2024 and has said the annex will be added to its E6(R3) guidance once complete. As of this writing the FDA has not published a final Annex 2 guidance or announced a date. The FDA's separate guidance on conducting clinical trials with decentralized elements, finalized in September 2024, remains the current U.S. reference.

Site-Level Implications

The points below summarize the operational themes of the annex. They are not a substitute for the guideline text, which sites should review against their own procedures.

Investigator Responsibility Does Not Move

The investigator remains responsible for trial conduct and for investigational product accountability even when visits, assessments, or dosing happen away from the site. Activities can be delegated; responsibility cannot.

Delegation to Local and Mobile Providers

Home health nurses and local clinicians who perform protocol assessments or administer product are carrying out delegated trial activities. Sites should expect to document their delegation, qualifications, and training in the same way as on-site staff.

Telehealth Visit Documentation

Remote visits are held to the same source-documentation standard as in-person visits. Protocols should state, assessment by assessment, what may be done remotely, and sites need a defined path for when a remote assessment cannot be completed.

Direct-to-Participant Product Shipment

Chain of custody, temperature control, accountability, and reconciliation obligations apply when product ships to a participant's home. Sites should confirm with each sponsor who performs which step and where the records are kept.

Informed Consent for Remote Participation

Consent materials should explain how remote participation works in practice: what technology is used, who will come to the home, how data are collected and shared, and what happens if an in-person visit becomes necessary.

Safety Information from Multiple Streams

When safety-relevant information can arrive from wearables, home visits, local providers, and health records, the site needs a clear process for who reviews each stream, how quickly, and how findings reach the investigator.

What Sponsors Should Do Now

For sponsors with EU sites, the working deadline is January 15, 2027. Protocols and monitoring plans for trials with decentralized elements should state which activities are performed on site, remotely, or centrally, and why that choice fits the risks of the trial. Agreements with home health, courier, and technology vendors should make clear who holds which GCP responsibility, because the annex does not relax sponsor or investigator obligations when a third party performs the work.

For U.S.-only programs, there is no new FDA compliance date yet. The sensible course is to design to the final ICH text now, since the FDA has indicated the annex will be incorporated into its E6(R3) guidance, and to keep following the FDA’s 2024 guidance on decentralized elements in the meantime.

Sponsors using real-world data sources should be ready to explain how each source was assessed as fit for purpose, how records can be traced back to their origin, and how access and governance are controlled when the data sit with a health system or data vendor.

How the Clinitiative Network Is Preparing

Under ClinFirst™ governance, network sites work from shared procedures for delegation, source documentation, and investigational product accountability. We are reviewing those procedures against the final Annex 2 text so that sites supporting trials with decentralized elements document remote visits, delegated providers, and shipped product in a consistent way. Sponsors planning a hybrid or decentralized protocol can ask us how these procedures apply to their study.

Planning a Trial with Decentralized Elements?

Talk with our team about site readiness for remote visits, delegated providers, and direct-to-participant shipment.